IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Launched by IMMATICS BIOTECHNOLOGIES GMBH · Jul 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called IMA402, designed to help patients with recurrent or hard-to-treat solid tumors. The main goals are to find the highest dose that is safe to use, understand how well the treatment works, and learn about any side effects it may cause. This study is currently looking for participants aged 18 and older who have a specific type of advanced cancer that has not responded to standard treatments, or who are not eligible for those treatments.

If you join the trial, you will receive IMA402 and be closely monitored by healthcare professionals to track your health and any changes in your tumor. It's important to note that participants cannot have other active cancers, be pregnant or breastfeeding, or have certain serious health conditions that may affect their safety during the trial. This research is a step towards finding new options for patients with challenging cancer cases, and your participation could help advance our understanding of this treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients ≥ 18 years old
• • Patients must have a specific pathologically confirmed and documented advanced and/or metastatic solid tumor indication
• • Patients must have received or not be eligible for all available indicated standard-of-care treatments
• • Measurable disease according to RECIST 1.1
• • Confirmed HLA status
• • ECOG Performance Status of 0 to 1
• • Adequate baseline hematologic, hepatic and renal function, acceptable coagulation status
• Exclusion Criteria:
• • Other active malignancies that require treatment or that might interfere with the trial endpoints (ongoing adjuvant anti-hormonal treatment is allowed)
• • The patient is pregnant or is breastfeeding
• • History of hypersensitivity to components of IMA402 or rescue medications, if no alternative treatment option is available
• • The patient has concurrent severe and/or uncontrolled medical disease. Any other health condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical trial because of safety concerns or compliance with clinical trial procedures
• • Patients with active brain metastases